Octozi vs Saama (2026)
Both automate the unglamorous middle of drug development, where trial data has to be cleaned, reconciled and reviewed before a submission can move. Saama is the incumbent, deployed across more than fifteen hundred studies at over fifty sponsors, and it names its own autonomy level for its agents, which is a disclosure almost nothing in this index offers. Octozi is newer and more specific about construction, combining language models with deterministic clinical algorithms rather than leaning on generation, stating human in the loop as an architectural commitment, and publishing a controlled study with named reviewers reporting throughput. The question neither answers plainly is whether one sponsor's data trains models serving another, which for a pharmaceutical buyer should be settled in contract before either system touches a study.
- It automates the data operations layer beneath drug development, cleaning, reconciling, reviewing and reporting trial data, which is where submission timelines actually slip.
- The architecture combines language models with deterministic clinical algorithms rather than relying on generation alone, and human in the loop is stated as an architectural commitment rather than a disclaimer.
- A published controlled study with named reviewers reports throughput results, which is more evidence than most vendors at this stage produce.
- Deployment scale is substantial and long standing across more than fifteen hundred studies at over fifty sponsors, so the platform has met the variety that breaks newer systems.
- It names its own autonomy level for its agents, which almost nothing in this index does, so a buyer knows what the system decides.
- Scope runs from study start through regulatory submission, covering more of the lifecycle than the data operations layer alone.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Octozi and Saama are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Octozi | Saama |
|---|---|---|
| Primary category | Clinical Trials AI | Clinical Trials AI |
| Founded | 2024 | Not recorded |
| Headquarters | New York, New York, United States | Campbell, California |
| Website | octozi.com | saama.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Octozi its top capability grade on AI Centrality and Autonomy and Oversight Model. Set against Saama, Octozi grades higher on Model Supply Chain Disclosure, AI Safety and PHI Stewardship and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Saama its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Set against Octozi, Saama grades higher on Clinical and Operational Evidence and Setting and Specialty Coverage. Its thinnest published disclosure sits on Model Supply Chain Disclosure and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Octozi or Saama?
On the axes where the AI Health Index separates them, Octozi grades higher on Model Supply Chain Disclosure, AI Safety and PHI Stewardship and AI Liability and Recourse, and Saama grades higher on Clinical and Operational Evidence and Setting and Specialty Coverage. Octozi leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Octozi and Saama differ most?
The widest separation the AI Health Index records between Octozi and Saama is on Model Supply Chain Disclosure, where Octozi grades B and Saama grades D. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Octozi and Saama grade the same?
The AI Health Index grades Octozi and Saama the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Octozi and Saama not disclosed?
At the last review, at least one of Octozi and Saama published thin or absent detail on Model Supply Chain Disclosure and AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Trials AI page.
Both process sponsor trial data and neither fully answers the question that matters most in that arrangement: whether one sponsor's data improves models serving another. Ask it explicitly and get the answer in contract. Octozi publishes no attestation despite describing its security architecture concretely, and its regulatory framing leaves the validation question open, which matters because any system touching regulated trial data carries qualification obligations and model updates inside a validated environment are not a settled matter. Saama publishes a governance framework with nothing measurable behind it and no security attestation. Neither publishes pricing.